Edgewise Therapeutics
Angela Peter, Ph.D. has a comprehensive work experience spanning various roles and organizations. Dr. Peter's most recent position, starting in August 2022, is as a Principal Scientist at Edgewise Therapeutics. Prior to this, they worked at Edgewise Therapeutics as a Scientist III from December 2019 to July 2022. Before joining Edgewise Therapeutics, Dr. Peter was a Research Assistant at the University of Colorado Boulder from 2014 to March 2020. Angela also served as a Postdoctoral Fellow at UCSD from 2008 to 2014 and as a Graduate Student Researcher at UCLA from 2003 to 2007.
Angela Peter, Ph.D., completed their education in a chronological manner. Angela first earned a Bachelor of Science (B.S.) degree in Microbiology from Colorado State University in the period between 1999 and 2003. During this time, their field of study focused on Microbiology and Immunology. Following this, they attended UCLA from 2003 to 2007, where they obtained a Doctor of Philosophy (Ph.D.) degree in Molecular, Cellular, and Integrative Physiology.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.